New drug combo for Ph+ ALL without transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- You are 18 years old or older.
- You are unable to receive a stem cell transplant (allo-HSCT).
- You have good kidney and liver function (blood tests will check this).
- You have not had any prior chemotherapy or CAR-T therapy for ALL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests olverembatinib plus blinatumomab for Philadelphia chromosome–positive (Ph+) ALL that is newly diagnosed. It aims to see how well this combination works and how safe it is for people who have not yet had standard leukemia medicines.
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
This trial tests a combination of immune-targeted therapy plus chemotherapy for people with a rare type of leukemia that doesn't clearly fit into the usual categories. The goal is to see if this approach can help control the leukemia better.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—together for people with a specific genetic type of acute lymphoblastic leukemia (Ph+ or BCR::ABL1-positive). The goal is to see how well the combination works for both newly diagnosed and relapsed/refractory cases.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.